Sponsored
The vaginal microbiome plays a critical role in women’s health, from infection resistance to fertility, yet it continues to remain underexplored. With DNA Genotek™’s OMNIgene™•VAGINAL collection kit, researchers and innovators are empowered to collect stablized samples with precision to support women’s healthcare research and development of healthcare for women.
![[Figure 1.] Syracuse Bio Campus – Home to LOTTE BIOLOGICS’ ADC and monoclonal antibody (mAb) manufacturing facilities](https://static.biospace.com/dims4/default/fe53c6f/2147483647/strip/true/crop/625x352+0+0/resize/1440x810!/format/webp/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fa0%2F5d%2F3ef4445240c7b416c1ddc66e7ad9%2F1-adc-mab-facility.png)
This year, LOTTE BIOLOGICS has ramped up its CDMO business expansion with the completion of an ADC (Antibody-Drug Conjugate) facility expansion at its Syracuse Bio Campus in the U.S. and the signing of its first production contract.
In the United States, only 31.4 % of phase II/III clinical trials in oncology are successfully completed1. The causes of this dramatic economic and time-consuming loss are, among others, protocol design and patient recruitment challenges.
The 2025 BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S. time) at the Boston Convention & Exhibition Center. This year, Taipei City Government is partnering with six Taipei-based biotech companies, including PanCAD.ai Co., Ltd., Instant NanoBiosensors Co., Ltd., Bened Biomedical Co., Ltd., Cancer Free Biotech Ltd., Xantho Biotechnology Co., Ltd., and Energenesis Biomedical Co., Ltd., to showcase their innovations at the Taiwan Pavilion (Booth #1645) in the Taipei Exhibition Area.
The Shift Toward Real-World, Patient-Centered Evidence
Founded in 2007, Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients with rare neurodegenerative diseases
SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may modify disease progression in Alzheimer’s and related tauopathies.
In October 2023, Sino Biological, Inc. opened its Center for Bioprocessing (C4B) in Houston, Texas. The C4B represents a considerable global expansion of the company’s contract research service capabilities.
Sino Biological, Inc. has successfully concluded the acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.
Q&A: Development Scientist at AGC Biologics Sara Morlacchi analyzes the growth of the cell therapy industry and barriers for cost and accessibility.